Cadila Healthcare

Zydus Lifesciences (earlier known as Cadila Healthcare) says Sentynl will make cash payments upon the achievement of certain regulatory milestones.

Accumulate Cadila Healthcare; target of Rs 445: KR Choksey

KR Choksey recommended accumulate rating on Cadila Healthcare with a target price of Rs 445 in its research report dated February 07, 2022.

Buy Cadila Healthcare; target of Rs 560: Sharekhan

Sharekhan is bullish on Cadila Healthcare has recommended buy rating on the stock with a target price of Rs 560 in its research report dated February 03, 2022.

Buy Cadila Healthcare; target of Rs 490: Motilal Oswal

Motilal Oswal is bullish on Cadila Healthcare has recommended buy on the stock with a revised price target (PT) of Rs. 490 in its research report dated February 04, 2022.

Hot Stocks | Here's why you should buy Maruti Suzuki, Cadila Healthcare for short term

Technically speaking, 16,800 is considered to be a crucial level because it coincides with the 78.6 percent retracement of the recent up move as well as the trend line support, says Sameet Chavan of Angel One

Cadila re-appoints Sharvil P Patel as MD for another five-year term

The company’s board based on the recommendation of the nomination and remuneration committee and subject to approval of the members of the company has approved the proposal to re-appoint Patel as the MD for a further period of five years till March 31, 2027, the drug firm said in a regulatory filing.

Cadila Healthcare Q3 PAT seen up 3.2% YoY to Rs 544 cr: Prabhudas Lilladher

Net Sales are expected to decrease by 0.2 percent Y-o-Y (up 0.1 percent Q-o-Q) to Rs 3,788.1 crore, according to Prabhudas Lilladher.

Buy Cadila Healthcare: target of Rs 720: Sharekhan

Sharekhan is bullish on Cadila Healthcare has recommended buy rating on the stock with a target price of Rs 720 in its research report dated December 28, 2021.

Cadila Healthcare Q2 PAT seen up 19% YoY to Rs 563.3 cr: Prabhudas Lilladher

Net Sales are expected to decrease by 3.5 percent Y-o-Y (down 8.4 percent Q-o-Q) to Rs 3,685.8 crore, according to Prabhudas Lilladher.

Cadila Healthcare enters pact with Shilpa Medicare for production of ZyCoV-D vaccine

The company has, "entered into a definitive agreement with Shilpa Medicare, via its wholly owned subsidiary, Shilpa Biologicals for production-supply of the ZyCoV-D vaccine drug substance from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka," Cadila Healthcare said in a regulatory filing.

Cadila Healthcare share price falls on sale of two brands

Purchaser is a part of the portfolio companies of PE firm True North and said the transaction is not a related party transaction.

Cadila Healthcare unit inks pact to sell two brands to Integrace

Zydus Healthcare Ltd, a wholly-owned subsidiary of the company, has inked the agreement with Integrace, a part of the portfolio companies of private equity firm True North.

Buy Cadila Healthcare target of Rs 695: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Cadila Healthcare has recommended buy rating on the stock with a target price of Rs 695 in its research report dated dated August 24, 2021.

Buy Cadila Healthcare; target of Rs 720: Sharekhan

Sharekhan is bullish on Cadila Healthcare has recommended buy rating on the stock with a target price of Rs 720 in its research report dated August 11, 2021.

Cadila: Vaccine opportunity unfolds

On conservative basis, for COVID vaccine opportunity, Cadila can at least add 16 per cent of FY21 sales revenue, on a full-year basis

Cadila Healthcare share price rises 7% after DCGI approves ZyCoV-D COVID vaccine

ZyCoV-D is the world’s first Plasmid DNA Vaccine for COVID-19

Buy Cadila Healthcare; target of Rs 670: Motilal Oswal

Motilal Oswal is bullish on Cadila Healthcare recommended buy rating on the stock with a target price of Rs 670 in its research report dated August 11, 2021.

What should investors do with Cadila Healthcare after Q1 earnings: buy, sell or hold?

The pharma company reported a 29 percent year-on-year jump in net profit at Rs 587 crore for the quarter ended June 30 led by strong growth in domestic formulation business and COVID-19 drug sales

Cadila Healthcare arm completes sale of animal health business for Rs 2,921 crore

"The transaction of sale and disposal is completed /closed today i.e. July 14, 2021," Cadila Healthcare said in a regulatory filing.

Cadila Healthcare Q1 PAT seen up 63.9% YoY to Rs 744 cr: KRChoksey

Net Sales are expected to increase by 8.7 percent Y-o-Y (up 5.4 percent Q-o-Q) to Rs 3,956 crore, according to KRChoksey.